Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis

William J. Weiss, Mark E. Pulse, Phung Nguyen, Kelly Peterson, Jessica Silva, Jerry W. Simecka, David Valtierra, Mojgan Sabet, David C. Griffith

Research output: Contribution to journalArticle

7 Scopus citations


The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.

Original languageEnglish
Article numbere01439
JournalAntimicrobial agents and chemotherapy
Issue number1
StatePublished - Jan 2018



  • KPC
  • Klebsiella pneumoniae carbapenemase
  • Meropenem
  • Pyelonephritis
  • Vaborbactam

Cite this